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Prelamin A causes progeria through cell-extrinsic
mechanisms and prevents cancer invasion
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Deﬁning the relationship between ageing and cancer is a crucial but challenging task. Mice
deﬁcient in Zmpste24, a metalloproteinase mutated in human progeria and involved in
nuclear prelamin A maturation, recapitulate multiple features of ageing. However, their short
lifespan and serious cell-intrinsic and cell-extrinsic alterations restrict the application and
interpretation of carcinogenesis protocols. Here we present Zmpste24 mosaic mice that lack
these limitations. Zmpste24 mosaic mice develop normally and keep similar proportions of
Zmpste24-deﬁcient (prelamin A-accumulating) and Zmpste24-proﬁcient (mature lamin
A-containing) cells throughout life, revealing that cell-extrinsic mechanisms are preeminent
for progeria development. Moreover, prelamin A accumulation does not impair tumour
initiation and growth, but it decreases the incidence of inﬁltrating oral carcinomas. Accord-
ingly, silencing of ZMPSTE24 reduces human cancer cell invasiveness. Our results support the
potential of cell-based and systemic therapies for progeria and highlight ZMPSTE24 as a new
anticancer target.
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A
geing and cancer are divergent consequences of the
accumulation of molecular alterations with time. These
changes activate cell senescence or apoptosis to prevent
cancer, collaterally reducing ﬁtness and regenerative potential1.
The study of the ageing–cancer relationship is hampered by its
complexity and duality, as ageing is caused by systemic and
cellular alterations, and age is the main cancer risk factor.
Disruption of the nuclear lamina, one of the cellular changes
involved in natural ageing2, underlies different syndromes
known as progeroid laminopathies3. Hutchinson-Gilford
progeria syndrome, mandibuloacral dysplasia and restrictive
dermopathy are caused by lamin A maturation defects due to
mutations in the LMNA and the ZMPSTE24 loci, the latter
encoding the metalloproteinase required for prelamin A
processing4–7. Altered lamin A processing has been linked to
senescence and upregulation of p53 targets, telomere erosion,
defective DNA repair, increased autophagy, deregulated miRNA
expression, epigenetic changes and overactivation of NF-kB
signalling at the cellular level8–14. At the systemic level, prelamin
A isoforms cause alterations in the somatotroph axis, changes in
glucose and lipid metabolism, and induction of chronic
inﬂammatory responses14,15.
The wide and large effect of alterations of lamin A and its
precursors on the pathways central for the control of cell viability
and systemic homoeostasis processes, which are very frequently
altered during oncogenesis, makes a potential link of nuclear
lamins with cancer very plausible. However, the studies
conducted so far have not established a clear connection16.
Zmpste24-deﬁcient and Lmna-knock-in mice have been
successfully used as models to study progerias and test potential
treatments for them17–19. Unfortunately, these mice have
important limitations that restrict the study of the relevance of
prelamin A in cancer: their shortened lifespan (4 months) is not
compatible with conventional tumour induction protocols, and
their concomitant systemic and cellular abnormalities make it
difﬁcult to dissect the effects of prelamin A on tumour biology4.
To circumvent these limitations, we describe herein the
generation of a novel mosaic mouse model in which Zmpste24-
deﬁcient cells—accumulating prelamin A–and Zmpste24-
proﬁcient cells—expressing mature lamin A—coexist in similar
proportions within the same individual, showing no overt
phenotype and normal levels of systemic parameters typically
altered in progeroid mice. Moreover, this model allowed us to
analyse the effects of prelamin A on tumour establishment and
progression in vivo.
Results
Zmpste24 mosaic mice display no progeroid phenotype. We
have generated a novel epigenetic-mosaic mouse model using
recombination-mediated cassette exchange (RMCE) (Fig. 1a
and Supplementary Fig. S1a), following a previously described
strategy20. The mice in this study were Zmpste24 /HprtZ24/þ
females (hereafter ‘mosaic’): null for the autosomal Zmpste24
locus, but containing an extra copy of the Zmpste24 gene
introduced at the Hprt locus of their X chromosome (Fig. 1a and
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Figure 1 | Absence of progeroid phenotype in Zmpste24 mosaic mice. (a) Breeding scheme. Zmpste24 /HprtZ24 male mice were bred with
Zmpste24þ /Hprtþ /þ female mice to yield female offspring that were either Zmpste24 /HprtZ24/þ (mosaic) or Zmpste24þ /HprtZ24/þ (HT-
control). (b) Western blot analysis of lamins A and C from control and mosaic neonatal ﬁbroblasts. Original immunoblots images are shown in
Supplementary Fig. S7. (c) Body weight versus age of HT-control, KO-control, Zmpste24 / and mosaic mice (n¼ 5 per genotype). Error bars represent
s.e.m. (d) Kaplan–Meier survival plot of mice with genotypes as in c (n¼8 per genotype). (e) Photographs of 4-month-old HT-control, Zmpste24 / , KO-
control and mosaic mice. (f) Lack of progeroid features in skin, thymus and spleen from mosaic mice. Asterisk-labelled bars indicate the depth of the
subcutaneous fat layer. Scale bar, 500mm.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3268
2 NATURE COMMUNICATIONS | 4:2268 |DOI: 10.1038/ncomms3268 | www.nature.com/naturecommunications
& 2013 Macmillan Publishers Limited. All rights reserved.
Supplementary Fig. S1a). Because of random X inactivation, two
types of cells should be present in them: those expressing
Zmpste24 from their Hprt locus and those not expressing
Zmpste24 at all. As controls, we generated Zmpste24þ /
HprtZ24/þ female mice (hereafter ‘HT-control’), which are hetero-
zygous for the autosomal Zmpste24 locus and thus would lack any
deleterious phenotype4, and Zmpste24 /HprtDZ24/þ female
mice (hereafter ‘KO-control’), which contain an insert in the Hprt
locus (DZ24) similar to the one in Zmpste24 /HprtZ24/þ mice,
but missing essential Zmpste24-coding sequences (Fig. 1a and
Supplementary Fig. S1b). To facilitate the monitoring of X
inactivation, we also introduced into the Hprt locus a CAGGS-
DsRed reporter cassette in cis with the Zmpste24 and DZ24 inserts
(Supplementary Fig. S1a,c). Mosaic, HT-control and KO-control
mice were born at the expected Mendelian ratios.
To ascertain the production of functional Zmpste24 metallo-
proteinase from the Zmpste24 gene at the Hprt locus, we obtained
protein extracts from mosaic pups and performed lamin A and
prelamin A western blot analysis. Although in the presence of
autosomal Zmpste24 (HT-control) just lamin A was detected, and
in its absence (KO-control) only prelamin A was observed, extracts
from newborn ear mosaic ﬁbroblasts contained lamin A and
prelamin A, consistent with the co-existence of Zmpste24-deﬁcient
and -proﬁcient cells (Fig. 1b). Interestingly, mosaic mice were
phenotypically indistinguishable from wild-type or HT-controls,
as they did not present the progeroid phenotypes and shortened
lifespan of Zmpste24 / or KO-control mice (Fig. 1c–f). These
results indicate that mosaic Zmpste24 complementation generates
lamin A-expressing cells that elicit reversion of the progeroid
phenotype induced by prelamin A in Zmpste24-deﬁcient mice.
Zmpste24-deﬁcient and -proﬁcient cells thrive equally. To
evaluate the persistence of prelamin A-expressing cells in mosaic
mice, we performed DsRed ﬂuorescence analysis of different
organs. Prelamin A-containing cells display replicative defects in
Zmpste24-deﬁcient mice11. If this was the case in mosaic mice, we
should detect a replacement of cells not expressing Zmpste24
by those expressing this metalloproteinase. Interestingly, all organs
studied from 1-year-old mosaic mice, double the maximum
lifespan of Zmpste24 / mice, contained ﬂuorescent (DsRed-
positive) and non-ﬂuorescent cells (Fig. 2a). Furthermore,
immunohistochemical labelling of DsRed and prelamin A in
hearts from mosaic mice conﬁrmed that DsRed-expressing cells
contained Zmpste24 that was able to process prelamin A, whereas
this lamin A precursor was accumulated in DsRed-negative cells
(Fig. 2b). To analyse whether cell substitution occurred with age, we
dissected tissues from 2-month-, 1-year- and 2-year-old mice and
measured their DsRed ﬂuorescence. We did not detect signiﬁcant
changes in the intensity of red ﬂuorescence in any organ except for
the heart, where a consistent increase of DsRed signal was apparent
(Fig. 2c). However, this increase was also detected in HT-control
and in Zmpste24þ /HprtDZ24/þ animals, which only contain
Zmpste24-proﬁcient cells, ruling out the possibility that it was
related to the effects of prelamin A (Supplementary Fig. S2). Then,
as red ﬂuorescence is an indirect reporter of Zmpste24 expression,
we conﬁrmed our results by immunoblotting of Zmpste24, lamin A
and prelamin A in tissues from 4-, 12- and 24-month-old mice
(Fig. 2d and Supplementary Fig. S3). Consistently, no signiﬁcant
changes on the levels of these proteins were detected.
To ﬁnely measure the proportions of Zmpste24-deﬁcient and
-proﬁcient cells in different tissues with age, we pyrosequenced
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Figure 2 | Zmpste24-deﬁcient cells are detected throughout lifespan of mosaic mice. (a) Fluorescence microscopy of DsRed-expressing cells in
tissues from Zmpste24þ /þHprtþ /þ (C ), mosaic and Zmpste24þ /HprtZ24/Z24 (Cþ ) mice. Scale bars, 100mm (heart) and 50mm (kidney).
(b) Immunohistochemical analysis of DsRed (left) and prelamin A (right) in mosaic hearts. Arrows correspond to a Zmpste24-deﬁcient cell (DsRed ,
prelamin Aþ ), whereas arrowheads point to a Zmpste24-proﬁcient cell (DsRedþ , prelamin A ). Scale bar, 10mm. (c) DsRed ﬂuorescent signal detection
by an In Vivo Imaging System in whole organs from mosaic mice at different ages, compared with the same organs from 1-year-old Zmpste24þ /þHprtþ /þ
(C ) and Zmpste24þ /HprtZ24/Z24 (Cþ ) mice. For comparison with DsRed signal in hearts from HT-control and Zmpste24þ /HprtDZ24/þ mice, see
Supplementary Fig. S2. (d) Western blot analysis of prelamin A and lamin A from skin, liver, lung and heart of 2-, 12- and 24-month-old mosaic mice.
A densitometry analysis of the immunoblots is also shown. Error bars represent s.e.m. n¼ 3.
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bisulphite-modiﬁed DNA. This approach allowed us to detect
methylation of speciﬁc CpG dinucleotides in the Zmpste24
promoter located at the Hprt locus, which shows maximum levels
of methylation in the inactive X chromosome (Fig. 3a). To set the
maximum methylation value, we analysed two lines of Zmpste24-
deﬁcient ear ﬁbroblasts isolated from mosaic mice by random
drift during serial passages in culture (Fig. 3a). These cells only
produce prelamin A, thereby representing the highest level of
methylation observable. CpG 3 and CpG 4 dinucleotides showed
methylation values consistently high in these Zmpste24-deﬁcient
cells. We focused on CpG 3 and set the 100% methylation level as
the average value obtained for this dinucleotide in Zmpste24-
deﬁcient cells. As expected, CpG 3 methylation in all tissues from
wild-type mice was negligible (Fig. 3a). We then analysed tissues
from mosaic mice and HT-control mice (Fig. 3b). If substitution
of Zmpste24-deﬁcient cells by Zmpste24-proﬁcient cells occurred,
the percentage of methylation in the Zmpste24 promoter should
decrease with age in the mosaic mice. However, methylation
levels did not decrease signiﬁcantly with time in mosaic tissues
and remained similar to the values obtained in HT-control tissues
between 2 months and 2 years, including the heart (Fig. 3b).
To further explore these in vivo observations, we studied
whether the presence of wild-type cells is able to rescue the
phenotype of Zmpste24-deﬁcient ﬁbroblasts in vitro. The growth
dynamics of co-cultures of adult ﬁbroblasts (AFs) explanted from
wild-type and Zmpste24-knockout mice closely resembled that of
wild-type AFs, suggesting that Zmpste24-deﬁcient AFs proliferate
better in the presence of wild-type cells (Supplementary Fig. S4a).
To analyse whether, as previously reported for LMNAD9
mouse AFs21, the presence of extracellular matrix (ECM) alone
was able to rescue the proliferative ability of Zmpste24-deﬁcient
AFs, we cultured them on ECM previously deposited by
wild-type or Zmpste24-deﬁcient AFs. Interestingly, both types
of ECM improved the replicative capacity of Zmpste24-deﬁcient
AFs, suggesting that an ECM production deﬁcit, and not the
lack of speciﬁc components of the ECM, underlies the reduced
proliferative ability of Zmpste24-deﬁcient cells in vitro
(Supplementary Fig. S4b).
Taken together, these results indicate that prelamin A
accumulation does not represent a selective disadvantage for
cells of mosaic mice, where Zmpste24-deﬁcient and -proﬁcient
cells coexist in similar proportions, and suggest that ECM-
mediated mechanisms contribute to the reversal of the phenotype
of Zmpste24-deﬁcient cells.
Progeria markers are rescued in mosaics. Because p53-target
genes are overexpressed in hearts from Zmpste24 / mice11, we
analysed cardiac p21, Atf3 and Igfbp3mRNA levels in mosaic mice.
Although Zmpste24-deﬁcient hearts showed overexpression of
these three p53-target mRNAs, the levels of these transcripts were
normal in mosaic hearts (Fig. 4a). To further explore this
observation, we used DsRed labelling to separate Zmpste24-
deﬁcient cells from Zmpste24-proﬁcient cells by microdissection of
mosaic hearts. Interestingly, p21 and Igfbp3 levels were not
signiﬁcantly different in Zmpste24-deﬁcient and -proﬁcient
cardiomyocytes from the same mosaic mouse (Fig. 4b). Together,
these results indicate that the upregulation of p53-target transcripts
in Zmpste24-deﬁcient mice is not a direct consequence of prelamin
A accumulation in each cell, but likely secondary to the progressive
organismal deterioration of these animals. We next analysed the
levels of biochemical markers and hormones deregulated in the
complete absence of Zmpste24 (refs 11,15). IGF1, glucose and
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Figure 3 | Mosaic mice keep similar proportions of Zmpste24-deﬁcient and -proﬁcient cells at all ages. (a) Bisulphite pyrosequencing strategy to
quantify the relative proportion of Zmpste24-deﬁcient and -proﬁcient cells. Four CpG sites around the Zmpste24 promoter were analysed in DNA from
Zmpste24-deﬁcient AFs isolated from mosaic mice (AF1 and AF2) and in DNA from six wild-type tissues (heart, liver, adipose tissue, kidney, lung and
muscle). Western blots show the progressive loss of mature lamin A and accumulation of prelamin A with serial passages of AF1 and AF2 cells, until
only prelamin A is detected (dashed rectangles). The percent methylation of CpG sites is depicted for each of the cell populations. CpG 3 was subsequently
used because of its low levels of methylation in wild-type tissues and consistent high values in the isolated ﬁbroblasts. 1F and 1R indicate the positions of
the oligonucleotides used (for sequences, see Supplementary Table S4). TSS, Zmpste24 transcription start site. (b) Quantitative Zmpste24 methylation
analysis by pyrosequencing in different organs from 2-, 12- and 24-month-old mosaic and HT-control mice (nZ3). Error bars represent s.e.m.
*Po0.05; **Po0.01; and two-tailed Student’s t-test.
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major urinary protein levels were normal in mosaic mice
(Fig. 4c,d). Thus, these animals appear healthy, despite
containing a high proportion of prelamin A-expressing,
Zmpste24-deﬁcient cells. All these observations further support
the idea that cell-extrinsic mechanisms are preeminent in the onset
and development of prelamin A-induced progeria.
Prelamin A accumulation does not affect tumour initiation. As
Zmpste24 mosaic mice contain prelamin A-expressing cells in a
normal environment, we used them to evaluate the potential role
of A-type lamins in cancer. To compare the tumour initiation
potential of prelamin A-expressing cells and normal lamin
A-expressing cells, we performed two protocols: topical 7,12-
dimethylbenz[a]anthracene (DMBA)–12-o-tetradecanoylphorbol-13-
acetate (TPA) application for the induction of skin papillomas22
and urethane injection for the generation of lung adenomas23.
We did not detect differences in tumour susceptibility between
HT-control and mosaic mice or in the number of tumours
expressing or lacking prelamin A in the latter animals
(Supplementary Fig. S5a–c). Consistent with these observations,
no signiﬁcant differences in Ki67 staining were detectable
between prelamin A-positive and -negative tumours
(Supplementary Fig. S5d). Thus, prelamin A does not affect the
susceptibility of epithelial cells from the skin or lung to neoplasia.
Prelamin A accumulation prevents cancer invasion. To test
whether prelamin A could have a role in cancer progression, we
performed an additional carcinogenesis protocol based on the
administration of 4-nitroquinoline 1-oxide (4-NQO) in drinking
water to induce squamous cell carcinomas of the upper digestive
tract24. This protocol produced a wide spectrum of neoplastic
lesions, from benign papillomas to inﬁltrating carcinomas. In
agreement with the above results, no differences were observed in
premalignant lesions (Fig. 5a). However, the proportion of mosaic
mice affected by inﬁltrating carcinomas of the oral cavity was
signiﬁcantly reduced, as compared with HT-controls (Fig. 5a).
Moreover, the proportion of oral inﬁltrating carcinomas with respect
to all carcinomas (carcinomas in situ plus inﬁltrating carcinomas)
was also strikingly lower in the mosaic mice (Fig. 5b). Interestingly,
although the numbers of carcinomas in situ expressing and not
expressing prelamin A by immunohistochemistry were comparable
in mosaic mice (Fig. 5c), the only two inﬁltrating carcinomas
observed in these animals lacked prelamin A staining (Fig. 5d).
To explore the mechanistic basis of this observation in a
human cancer context, we used small interfering RNAs (siRNAs)
to silence ZMPSTE24 in cell lines from human oral inﬁltrating
carcinomas (SCC-40 and SCC-2) and compared their RNA
expression proﬁles with those of mock-treated cells. ZMPSTE24
silencing produced prelamin A accumulation and induced
relevant changes in gene expression. Interestingly, gene set
enrichment analysis revealed that among the pathways most
signiﬁcantly altered in ZMPSTE24-silenced SCC-40 and SCC-2
cells are those involved in ECM composition and in cell–ECM
interactions (Supplementary Tables S1–S3). This observation,
together with the well-established relationship between ECM and
cancer cell invasiveness, prompted us to test whether prelamin A
accumulation also affected the invasive properties of these cancer
cell lines. Consistent with our in vivo results, in vitro invasion
assays with ZMPSTE24-silenced SCC-40 and SCC-2 cells showed
that the accumulation of prelamin A caused a signiﬁcant decrease
of their invasive potential (Fig. 5e).
To study whether this effect was speciﬁc to oral cancer, we
analysed breast (MDA-MB-231) and lung (A549) cancer cells,
observing a reduction in their invasive ability in the presence of
prelamin A (Fig. 5e). Genome-wide expression proﬁles of these
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Figure 4 | Rescue of molecular and systemic progeria markers in mosaic mice. (a) Transcriptional qPCR analysis of p53-target genes (Cdkn1a, Igfbp3 and
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used for microdissection, is shown on the right. Scale bar, 100mm. (c) Plasma levels of IGF1 and blood glucose concentration in HT-control, Zmpste24 /
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(d) Representative picture of SDS–PAGE analysis of major urinary proteins (MUPs) content in urine from mice of each of the indicated genotypes.
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cells upon ZMPSTE24 silencing also pointed to the pathways
involved in the synthesis of precursors of ECM components as
the most signiﬁcant commonly altered molecular routes
(Supplementary Table S1). In addition, all four cell lines studied
showed signiﬁcant changes in expression of main components of
the ECM–receptor interaction pathways, such as ITGA5, CD47 or
DAG1 (Supplementary Table S2). Thus, ZMPSTE24 silencing in
oral, breast and lung cancer cell lines causes prelamin A
accumulation and rewiring of the ECM-related cellular pathways,
which could account for their reduced invasive potential.
Interestingly, all four ZMPSTE24-silenced cancer cell lines that
were analysed showed alterations in routes involved in proteo-
glycan synthesis (chondroitin sulphate and/or heparan sulphate
(HS)) (Supplementary Tables S1,S3), showing expression changes
indicative of increased production of oversulfated forms of both
ECM components.
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Figure 5 | Prelamin A accumulation prevents cancer invasion. (a) Percentage of HT-control (n¼ 17) and mosaic (n¼ 17) mice affected by oral lesions
with the indicated histology. CIS, carcinoma in situ; Hyp, hyperplasia; Inf. Ca., inﬁltrating carcinoma; L/M-Dys, light/moderate dysplasia; S-Dys, severe
dysplasia. (b) Number and proportion of in situ and inﬁltrating oral carcinomas in each group. (c) Representative photomicrographs of positive (bottom)
and negative (top) prelamin A staining in oral CIS from mosaic mice. The percentage of prelamin A-positive and -negative CIS is plotted. A total of 17 CIS
were analysed by prelamin A immunohistochemistry. Scale bar, 100mm. (d) Representative photomicrographs of a prelamin A-negative inﬁltrating
carcinoma from a mosaic mouse. Arrowheads point at nests of invasive cancer cells. Scale bars, 100mm (left panel) and 50mm (right panel). (e) Effect of
ZMPSTE24 silencing on the invasiveness of SCC-40, SCC-2, A549 and MDA-MB-231 cancer cell lines. Left panels: western blots showing the accumulation
of prelamin A upon ZMPSTE24 (siZ24) versus scrambled (siScr) silencing. Right panels: representative pictures and average number of invasive ZMPSTE24-
interfered and scrambled-treated cells. The assays were carried out at least in triplicate, and results are expressed as mean±s.e.m. *Po0.05; **Po0.01;
and Fisher’s exact test. Scale bars, 100mm.
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Discussion
Human lifespan extension is rising the incidence of pathologies
associated with age, of which cancer is the second most lethal, only
after cardiovascular disease25. Age is the main risk factor for cancer
incidence, but the links between ageing and cancer remain difﬁcult
to deﬁne because of the complex relationship between both
processes26. Besides causing accelerated ageing syndromes,
immature lamin A forms accumulate with advancing age in non-
progeroid cells and have been linked to the activation of tumour-
suppressor mechanisms2,11. Accordingly, one potential role for
prelamin A would be the protection against cancer.
Because of their short lifespan, mouse models of progeroid
laminopathies are not suitable for the analysis of the effects of
lamin A precursors on cancer. To circumvent this limitation, we
have created a novel mosaic mouse model containing prelamin
A-accumulating and normal cells. These mice do not suffer from
premature death and, therefore, are suitable to study the effects of
this lamin A precursor on tumour initiation and progression.
Our thorough analysis of mosaic mice has revealed that
prelamin A accumulation does not represent a selective disadvan-
tage for cells, demonstrating that cell-extrinsic mechanisms are
preeminent in progeria pathogenesis. This ﬁnding was unexpected,
as abnormal prelamin A processing causes defects in essential cell
pathways9–11,27–32. In line with our observations, Song et al.33
have recently shown that exposure of progeroid Zmpste24-
deﬁcient muscular-derived stem/progenitor cells to wild-type
muscular-derived stem/progenitor cells rescues their myogenic
differentiation defect in vitro. Even in the light of this observation,
the complete absence of progeroid features in our mosaic mice is a
remarkable and encouraging ﬁnding.
Our results suggest that the positive effects of Zmpste24-
proﬁcient cells on Zmpste24-deﬁcient cells are mediated
by a combination of structural and diffusible factors. Thus, the
replicative defects shown by Zmpste24-deﬁcient AFs grown
in vitro are rescued by the presence of ECM. This observation
recapitulates the results previously obtained with LMNAD9
mouse AFs21. In addition, circulating levels of systemic factors
such as IGF1 are restored in mosaic mice. Although, from our
observations, we cannot distinguish whether the normal levels of
IGF1 are responsible for the lack of progeroid phenotype or a
consequence of it in mosaic mice, the positive effect of the
administration of this hormone to Zmpste24-deﬁcient mice
supports the existence of a causative role for IGF1 on the
prevention of progeria15.
Moreover, our ﬁndings highlight the potential relevance of
both systemic and cell-based or gene-correction treatments for
progeroid syndromes and pathologies associated with normal
ageing18,34. In this regard, parabiosis experiments, in which the
circulatory systems of young and old mice are artiﬁcially
connected, have already shown the potential of systemic factors
to prevent certain characteristics of natural ageing35,36. One of
these, the TGF-b superfamily member GDF11, has been recently
identiﬁed as a circulating factor in young mice that declines with
age and is able to reverse age-related cardiac hypertrophy when
administered to old mice35. On the other hand, the generation of
genetically corrected induced pluripotent stem cells from
Hutchinson-Gilford progeria syndrome ﬁbroblasts, or the
feasibility to perform in vivo genomic editing, creates novel
treatment options for these pathologies that need to be further
explored37–40. Our results, showing that full reversion of the
progeroid phenotype is compatible with the persistence of a high
proportion of prelamin A-expressing cells, reinforce the potential
held by gene-correction and cell-based therapeutic approaches to
tackle these dramatic progeroid syndromes.
Cancer induction experiments performed in mosaic mice
indicate that prelamin A does not affect tumour initiation, but it
prevents cancer invasion. This was conﬁrmed in human oral, lung
and breast cancer cell lines, suggesting that cancer invasion might
display non-oncogenic addiction to the ZMPSTE24 metallopro-
teinase41. Molecular surveillance of the acquisition of invasive
properties constitutes a plausible cancer control checkpoint.
Thus, although the loss of p53 has no effect on the number of
mutant-Kras-induced lung tumours or mutant-Braf-induced
colorectal adenomas, its presence prevents the progression of
benign adenomas into adenocarcinomas42–44. The accumulation
of immature lamin A isoforms might constitute one of those
mechanisms that could become stronger with time to compensate
for the increased cancer risk inherent to ageing2.
The observed expression changes in the pathways involved in
ECM composition upon ZMPSTE24 silencing in human cancer
cell lines indicate that prelamin A might exert this protective
effect through a cell-extrinsic mechanism. Actually, the ECM and
its interactors are main characters of cancer invasion45. Although
increased levels of proteoglycans have been linked to enhanced
invasion, recent work has shown that both chondroitin sulphate
and HS can exert different roles depending on their speciﬁc
modiﬁcations (such as oversulfation) and microenvironment46,47.
Moreover, synthetic HS mimetics have been proposed as anti-
cancer agents able to inhibit tumour progression and metastasis,
opening the possibility that speciﬁc natural HS isoforms might
have similar anticancer roles48. The potential cell-extrinsic effect
of prelamin A accumulation on prevention of cancer cell invasion
is supported by the fact that the proportion of carcinomas
displaying invasive properties in mosaic mice (6%) is far below
half of that observed in HT-controls (39%). On the other hand,
the only two oral inﬁltrating carcinomas observed in mosaic mice
lacked prelamin A expression, and this would be consistent with a
cell-autonomous effect of prelamin A on invasion prevention.
Further work involving prelamin A expression analysis on a
much larger number of inﬁltrating carcinomas will be required to
clarify this issue.
In summary, we have developed a novel mosaic mouse model
constituted by prelamin A-accumulating cells and mature lamin
A-expressing cells in similar proportions, which shows no overt
phenotype. Besides representing a useful tool for the study of the
relevance of prelamin A in cancer initiation and progression, the
molecular and cellular characterization of these mice highlights
the importance of cell-extrinsic mechanisms for the establishment
of laminopathy-based progerias. Moreover, it suggests that
cell/gene therapies and supplementation of systemic factors hold
great potential to tackle these degenerative diseases. These
approaches could be combined with the pharmacological
strategies already proven to work in animal models that are
currently being evaluated in clinical trials19. In addition, the role
of prelamin A against cancer invasion suggests that ZMPSTE24
metalloproteinase could be an attractive new target for cancer
therapy.
Methods
Generation of the HprtZ24 allele. The RP23-227I2 BAC clone was modiﬁed by
the introduction of a pgk/EM7-Neo/KanR-CAGGS-DsRed cassette, permitting
positive selection in bacteria (with kanamycin) and eukaryotic cells (with G418)
and controlling the expression of the ﬂuorescent protein DsRed. For the generation
of the pgk/EM7-Neo/KanR-CAGGS-DsRed cassette, elements from three different
plasmids were used: pCEI1, MG1 and pDsRed-Monomer-N1. pCEI1 was described
in the original paper introducing the RMCE technique20. This plasmid contains the
Neo/KanR gene controlled by the pgk/EM7 promoter and ﬂanked by mini arms of
homology for the sacBII gene, which permit insertion of the resistance cassette in
the BAC by homologous recombination in bacteria. The MG1 plasmid was created
by H.M.P. and contains the CAGGS promoter from the pCAGGS vector49, but
with a more versatile cloning site. The pDsRed-Monomer-N1 plasmid (Clontech)
contains the cDNA for the Monomer-N1 version of the red ﬂuorescent protein
DsRed. First, the NotI site from pDsRed-Monomer-N1 was destroyed. For that
purpose, this plasmid was linearized by NotI digestion, the protruding ends were
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blunted with Klenow and the plasmid was religated and transformed in competent
Escherichia coli cells to generate pDsRed-Monomer-N1-NotI-Dest. After that, the
MG1 plasmid was digested with AﬂII, a 1,759-bp fragment containing the CAGGS
promoter was isolated and blunted with Klenow, and that fragment was cloned into
pDsRed-Monomer-N1-NotI-Dest that had been previously linearized with HindIII
and EcoRI, blunted with Klenow and dephosphorylated, to generate the pCAGGS-
DsRed-Monomer-N1 plasmid. Finally, pCAGGS-DsRed-Monomer-N1 was
digested with HindIII and AﬂII to isolate a 2,750-bp fragment containing the
CAGGS-DsRed-Monomer-N1 cassette, which was blunted with Klenow and
cloned into pCEI1, previously linearized with BamH1, blunted with Klenow and
dephosphorylated. This produced the pCEI1-CAGGS-DsRed-Monomer-N1
plasmid. This plasmid can be used to introduce kanamycin/G418-resistance ability
and DsRed expression into any BAC containing the sacBII gene. This vector was
linearized with NotI and electroporated into electrocompetent EL350 cells that had
been previously transformed with the RP23-227I2 BAC according to previously
described protocols50. To isolate recombinant clones containing the BAC modiﬁed
with the pgk/EM7-Neo/KanR-CAGGS-DsRed cassette, chloramphenicol and
kanamycin selection was applied (the backbone from the BAC provides
chloramphenicol resistance and the pgk/EM7-Neo/KanR-CAGGS-DsRed cassette
provides kanamycin resistance). The identity of the BAC was checked by digestion
with restriction enzymes, BAC DNA was isolated from a positive EL350 clone, and
it was retransformed into DH10B bacteria for large-scale isolation of the modiﬁed
BAC, as previously described20. The HprtZ24 allele was generated following a
strategy very similar to that previously described20.
Analysis of BAC insert integrity by array CGH. Four recombinant embryonic
stem (ES) cell clones (A1, A3, A10 and A12) were selected for detailed analysis of
BAC insert integrity, as partial insert deletions have been described in ES cell clones
generated by RMCE20. Insert integrity was analysed using a custom Roche
Nimblegen CGH 4-plex Array. Each of the four subﬁelds of the array contained
two different regions: a high-resolution region, made of 45,000 probes evenly
distributed between genomic coordinates 120,627,332 and 120,942,331 of mouse
chromosome 4 excluding repetitive DNA regions (1 probe every 4 bp), and a
low-resolution region, consisting of 25,000 probes homogenously scattered along
the whole mouse genome (one probe every 100 kb). The high-resolution region
spans the whole BAC insert, plus two additional 64,171-bp long sequences,
corresponding to the mouse chromosome 4 regions ﬂanking the sequence
contained in the BAC insert at its 50 and 30 ends. The array-CGH results were
analysed with SignalMap, which permitted the detection of a 38,200-bp deletion in
clone A2, corresponding approximately to coordinates 120,742,750–120,780,950 of
mouse chromosome 4, and thus containing the ﬁrst seven exons of Zmpste24. No
alterations were observed in inserts from clones A1, A3 and A12 (Supplementary
Fig. S1b).
Mouse strains. Animal experiments were conducted in accordance with the
guidelines of the Committee on Animal Experimentation of the University of
Oviedo. Mutant mice deﬁcient in the Zmpste24 metalloproteinase have been
described previously4. HprtZ24 and HprtDZ24 mice were obtained from A3 and A2
ES cell clones, respectively (Supplementary Fig. S1b). Zmpste24 /HprtZ24/þ
mice were obtained by crossing Zmpste24þ / male mice with HprtZ24/þ female
mice to produce Zmpste24þ /HprtZ24 males and Zmpste24þ /HprtZ24/þ
females. These mice were backcrossed with Zmpste24þ / mice to produce
Zmpste24 /HprtZ24 male mice. Those males were subsequently backcrossed
with Zmpste24þ / mice to produce mosaics and HT-controls. Zmpste24 /
HprtDZ24/þ mice were obtained by crossing Zmpste24þ / male mice with
HprtDZ24/þ female mice to get Zmpste24þ /HprtDZ24 male mice and
Zmpste24þ /HprtDZ24/þ female mice, which were backcrossed with
Zmpste24þ / mice to obtain KO-controls. Mosaic mice were genotyped by a
combination of conventional and quantitative PCR (Supplementary Fig. S6).
In Vivo imaging system. For whole-organ DsRed imaging, fresh organs were
placed on black cards and analysed for ﬂuorescence using the in vivo imaging
system (Xenogen). DsRed was excited at 570 nm and detected at 600 nm. Data were
collected and analysed using Living Image software v3.1 (Xenogen).
Bisulphite pyrosequencing assays. Sodium bisulphite modiﬁcation of 0.5 mg
genomic DNA isolated from various tissues was carried out with the EZ DNA
Methylation Kit following the manufacturer’s protocol. Bisulphite-treated DNA
was eluted in 15 ml, and 2 ml were used as template for each PCR. The set of primers
for PCR ampliﬁcation and sequencing was designed using a speciﬁc software pack
(PyroMark assay design version 2.0.01.15). Primers were designed to hybridize
with CpG-free sites to ensure methylation-independent ampliﬁcation (see
Supplementary Table S4). PCR was performed with biotinylated primers to facil-
itate the conversion of the PCR product to single-stranded DNA templates.
Vacuum Prep Tool (Biotage, Sweden) was used to prepare single-stranded PCR
products according to the manufacturer’s instructions. Pyrosequencing reactions
and methylation quantiﬁcation were performed in a PyroMark Q24 System version
2.0.6 (Qiagen). Graphs of methylation values show bars identifying CpG sites with
values ranging from 0 to 100%.
Blood and plasma parameters. Mice were fasted for 5 h to avoid alterations in
blood parameters due to food intake previous to measurements. Blood glucose was
measured with an Accu-Chek glucometer (Roche Diagnostics) using blood from
the tail vein. For other parameters, blood was extracted directly from the man-
dibular sinus after anesthetizing mice with isoﬂurane. To obtain plasma, blood was
centrifuged immediately after collection at  3,000 g and 4 C, and the supernatant
was collected and stored at  80 C until analysis. Plasma IGF1 concentration was
determined using the R&D Systems Quantikine ELISA kit, according to the
manufacturer’s instructions.
Carcinogenesis protocols and analysis of tumours. Mice were all female lit-
termates aged 6–8 weeks at the start of tumour induction protocols. For the
generation of skin tumours, mice were shaved and treated with a single dose of
DMBA (Sigma; 25mg in 200 ml acetone). Subsequently, mice were treated twice
weekly with TPA (Sigma; 200 ml of 10 4 M solution in acetone) for 12 consecutive
weeks. Mice were killed 17 weeks after the start of treatment, and tumours were
either snap-frozen in liquid nitrogen or ﬁxed and processed for histological studies.
For the generation of lung tumours, mice were intraperitoneally injected with
1 g kg 1 of urethane (Sigma) once a week for 8 consecutive weeks. Mice were killed
at 28 weeks following the initial urethane injection. Then, lungs were ﬁxed in 4%
paraformaldehyde, parafﬁn-embedded, sectioned and stained with haematoxylin
and eosin for morphological examination. For the generation of upper digestive
tract tumours, a stock solution of the carcinogen 4-NQO (Sigma) was prepared
weekly in propylene glycol at 5mgml 1 and stored at 4 C. Mice were provided
drinking water containing 4-NQO (100 mgml 1) ad libitum during the treatment.
After a 20-week carcinogen treatment, mice were kept alive for 2 more weeks and
killed. Blocks containing the tongues together with the lower mandibles of mice
were dissected immediately, ﬁxed in 4% paraformaldehyde, decalciﬁed if necessary,
parafﬁn-embedded, sectioned and stained with haematoxylin and eosin for
pathological examination.
Gene-silencing and invasion assays. For gene-silencing experiments, cells were
transfected with 50 nM ﬁnal concentration of ZMPSTE24 or negative-control
Stealth RNAi siRNAs (Life Technologies; catalogue numbers: HSS115696 and
HSS115697 for human ZMPSTE24 and 12935-300 for negative-control scramble
siRNA) using Lipofectamine RNAi Max (Life Technologies) in Opti-MEM I
Reduced Serum Medium without serum (Gibco) following the manufacturer’s
instructions. In vitro invasion potential was evaluated using 24-well Matrigel-
coated invasion chambers with an 8 mm pore size (BD Biosciences). For SCC-40
and A549 cell lines, 5 104 and 3 104 cells, respectively, were allowed to invade
for 48 h using 10% fetal bovine serum as chemoattractant. In the case of SCC-2 and
MDA-MB-231 cells, the invasion ability of 2.5 104 cells was evaluated for 24 h,
using 5% fetal bovine serum as chemoattractant. Cells that reached the lower
surface were stained with crystal violet and counted under the microscope.
Gene expression arrays. Global RNA expression proﬁling was done using Illu-
mina HumanHT-12 version 4 beadchip. Data were quantile normalized and ana-
lysed using the bioconductor (http://www.bioconductor.org/), lumi (http://
www.bioconductor.org/packages/2.0/bioc/html/lumi.html) and limma packages,
and then P-value was adjusted for multiple testing.
Gene set enrichment analysis. Gene set enrichment analysis (GSEA) was per-
formed as described51. For data analysis, we used GSEA release 3.4 and MSigDB
release 3.0 (http://www.broadinstitute.org/gsea/index.jsp). Weighted enrichment
scores were calculated with gene expression lists ranked by signal to-noise ratio.
The number of permutations was set to 1,000. Analyses were focused on curated
gene sets from the canonical pathway subcollection.
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